Peptides for skin: what they do and what's proven

Peptides for skin are short chains of amino acids used to send, carry, or block biological signals in the skin. Collagen, elastin, and the other structural proteins of the dermis are themselves made of amino acids, and some of their breakdown fragments act as signals that prompt repair. Much of skin-peptide research starts from that observation: if a fragment signals the skin to rebuild, a synthetic version might do the same.

In practice, "peptides for skin" covers two very different worlds. One is cosmetics, where peptides are ingredients in over-the-counter creams and serums. The other is compounded therapeutic peptides, prepared by a licensed pharmacy for an individual patient on a prescriber's order. The molecules sometimes overlap — GHK-Cu appears in both — but the regulation, the formulation standards, and the claims that can be made differ substantially.

Cosmetic peptide products are regulated as cosmetics. They may not claim to treat disease or change the body's structure, and their supporting data are often manufacturer-sponsored studies of the finished product. Concentrations are frequently undisclosed.

Compounded peptides are prepared by a licensed 503A pharmacy for a specific patient on a valid prescription, under pharmacy-compounding standards and FDA rules governing which bulk substances may be used. That is also why regulatory status matters: a peptide's eligibility for 503A compounding depends on FDA's bulk-substance determinations, which are tracked on our FDA peptide status tracker. Newtropin connects licensed providers with a licensed 503A compounding partner; it does not prescribe, compound, or dispense.

Copper peptides are peptides bound to a copper ion, and GHK-Cu — the copper complex of the tripeptide glycyl-histidyl-lysine — is the one the research is actually about. It is endogenous: it occurs in human plasma, and its concentration declines with age. Published work describes stimulation of collagen, elastin, and glycosaminoglycan synthesis together with regulation of the enzymes that break matrix down — a pattern of organized remodeling rather than simple accumulation.

The clinical evidence is strongest for topical use, where controlled and open-label studies have reported improvements in skin density, elasticity, and fine lines, with effects that varied by formulation. "Copper peptide" on a label does not guarantee the characterized complex, which is a meaningful distinction when comparing a product to the literature. The full compound profile is on the GHK-Cu peptide page; dose questions are covered in GHK-Cu dosage, and what realistic outcomes look like in GHK-Cu injection before and after.

Two named blends dominate current searches. The GLOW peptide stack combines GHK-Cu with BPC-157 and TB-500, on the rationale that matrix remodeling, angiogenic signaling, and cell migration are complementary steps in repair. KLOW adds KPV, an anti-inflammatory tripeptide derived from α-MSH.

Neither blend has been studied as a combination in published human trials, the names carry no standardized formulation, and BPC-157, TB-500, and KPV each faced an unfavorable FDA proposal in July 2026. Both posts break the evidence down component by component.

Hair follicles share biology with skin, and GHK-Cu has been studied for effects on dermal papilla cells and follicle size in preclinical models. The clinical hair evidence is thinner than the skin evidence, and no peptide is an FDA-approved hair-loss treatment. Our guide to peptides for hair growth compares the peptides that have been studied with established options such as oral minoxidil and biotin.